Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, Wedbush Analyst Says

Replimune Group (NASDAQ:REPL) had its price target lifted by equities research analysts at Wedbush from $18.00 to $19.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price target suggests a potential upside of 174.17% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. HC Wainwright upgraded shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Monday, October 27th. Piper Sandler upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a research report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price for the company in a research note on Monday, October 20th. Finally, Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $3.00 to $13.00 in a research report on Monday, October 20th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Replimune Group presently has an average rating of “Hold” and an average price target of $10.00.

Replimune Group Stock Down 1.0%

Shares of NASDAQ REPL opened at $6.93 on Wednesday. The stock has a market cap of $572.21 million, a PE ratio of -2.01 and a beta of 0.73. The business has a fifty day moving average of $8.82 and a two-hundred day moving average of $7.22. Replimune Group has a 52-week low of $2.68 and a 52-week high of $14.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 6.31 and a current ratio of 5.60.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.08. As a group, equities research analysts expect that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In related news, insider Christopher Sarchi sold 5,208 shares of Replimune Group stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $9.10, for a total value of $47,392.80. Following the completion of the sale, the insider directly owned 123,088 shares in the company, valued at $1,120,100.80. This trade represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kapil Dhingra sold 3,169 shares of the company’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,625 shares of company stock worth $257,607 in the last ninety days. 5.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently bought and sold shares of REPL. Fcpm Iii Services B.V. raised its position in shares of Replimune Group by 6.4% during the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after acquiring an additional 248,672 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Replimune Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock worth $14,579,000 after purchasing an additional 9,707 shares during the period. Braidwell LP increased its holdings in Replimune Group by 550.3% in the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after purchasing an additional 2,327,205 shares during the last quarter. Balyasny Asset Management L.P. lifted its stake in Replimune Group by 507.4% in the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after buying an additional 2,195,448 shares during the period. Finally, Readystate Asset Management LP boosted its holdings in Replimune Group by 1,296.2% during the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock worth $10,982,000 after buying an additional 2,433,292 shares during the last quarter. 92.53% of the stock is owned by institutional investors.

Key Stories Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: Piper Sandler raised its price target to $14 and reaffirmed an “overweight” rating — signaling roughly ~100% upside from current levels. Piper Sandler price target raise
• Positive Sentiment: Wedbush boosted its price target to $19 and kept an “outperform” call, implying substantial upside vs. the current share price. Wedbush raises price target to $19
• Positive Sentiment: Replimune amended its Hercules loan agreement to strengthen its funding runway, lowering near-term financing risk and giving the company more time to advance clinical programs. Replimune amends Hercules loan
• Positive Sentiment: Q3 fiscal results included an EPS beat vs. consensus (reported loss per share less negative than expected) and a corporate update — a modest fundamental positive that reduces near-term execution risk. Q3 financial results and corporate update
• Neutral Sentiment: Brokerages’ consensus remains an average “Hold,” which can limit buying momentum despite isolated bullish calls. Analysts give REPL average ‘Hold’
• Neutral Sentiment: Coverage notes repeatedly describe analysts as “neutral” on healthcare names including REPL — supportive news is present but not yet enough to flip the consensus. Analysts neutral on healthcare stocks
• Neutral Sentiment: Pre-earnings notices and coverage (now superseded by results) contributed to short-term headline volume but did not materially change the consensus outlook. Projected to post quarterly earnings

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.